Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review

Detalhes bibliográficos
Autor(a) principal: Chade,Daher C.
Data de Publicação: 2009
Outros Autores: Shariat,Shahrokh F., Dalbagni,Guido
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382009000600002
Resumo: The management of non-muscle-invasive urothelial carcinoma of the bladder (UCB) is a challenge for physicians and patients alike. This is largely due to the heterogeneous natural history of this disease, in which tumors range from indolent to rapidly progressive and eventually fatal. Moreover, the high rate of recurrence and progression cause significant morbidity, expense, and detriment to quality of life. The advent of effective and safe intravesical therapies has improved the management of non-muscle-invasive UCB. Nevertheless, despite over 30 years of research and clinical experience, the mechanism, risks, benefits, and optimal regimens and treatment algorithms remain unclear. Although immunotherapy with bacillus Calmette-Guerin (BCG) has been the mainstay of intravesical treatment and represents a significant advance in the interaction of immunology and oncology, its clinical effectiveness is accompanied by a wide range of adverse events. Here, we review the literature on intravesical immunotherapy and chemotherapy with the aim of evaluating the clinical utility of the different treatments and providing recommendations. Many studies over the years have compared efficacy and toxicities of different agents and regimens, and certain conclusions are now well supported by high-level evidence. Future perspectives and promising advances in drug development are discussed and areas of improvement are identified in order to promote better cancer control and decrease the rate and severity of side-effects.
id SBU-1_4efdc1c277beb7b438cfa698cfb81bba
oai_identifier_str oai:scielo:S1677-55382009000600002
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical reviewurinary bladder neoplasmsmycobacterium bovisadministration/intravesicalneoplasm recurrence/localantineoplastic agentsThe management of non-muscle-invasive urothelial carcinoma of the bladder (UCB) is a challenge for physicians and patients alike. This is largely due to the heterogeneous natural history of this disease, in which tumors range from indolent to rapidly progressive and eventually fatal. Moreover, the high rate of recurrence and progression cause significant morbidity, expense, and detriment to quality of life. The advent of effective and safe intravesical therapies has improved the management of non-muscle-invasive UCB. Nevertheless, despite over 30 years of research and clinical experience, the mechanism, risks, benefits, and optimal regimens and treatment algorithms remain unclear. Although immunotherapy with bacillus Calmette-Guerin (BCG) has been the mainstay of intravesical treatment and represents a significant advance in the interaction of immunology and oncology, its clinical effectiveness is accompanied by a wide range of adverse events. Here, we review the literature on intravesical immunotherapy and chemotherapy with the aim of evaluating the clinical utility of the different treatments and providing recommendations. Many studies over the years have compared efficacy and toxicities of different agents and regimens, and certain conclusions are now well supported by high-level evidence. Future perspectives and promising advances in drug development are discussed and areas of improvement are identified in order to promote better cancer control and decrease the rate and severity of side-effects.Sociedade Brasileira de Urologia2009-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382009000600002International braz j urol v.35 n.6 2009reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/S1677-55382009000600002info:eu-repo/semantics/openAccessChade,Daher C.Shariat,Shahrokh F.Dalbagni,Guidoeng2010-01-15T00:00:00Zoai:scielo:S1677-55382009000600002Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2010-01-15T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review
title Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review
spellingShingle Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review
Chade,Daher C.
urinary bladder neoplasms
mycobacterium bovis
administration/intravesical
neoplasm recurrence/local
antineoplastic agents
title_short Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review
title_full Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review
title_fullStr Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review
title_full_unstemmed Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review
title_sort Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review
author Chade,Daher C.
author_facet Chade,Daher C.
Shariat,Shahrokh F.
Dalbagni,Guido
author_role author
author2 Shariat,Shahrokh F.
Dalbagni,Guido
author2_role author
author
dc.contributor.author.fl_str_mv Chade,Daher C.
Shariat,Shahrokh F.
Dalbagni,Guido
dc.subject.por.fl_str_mv urinary bladder neoplasms
mycobacterium bovis
administration/intravesical
neoplasm recurrence/local
antineoplastic agents
topic urinary bladder neoplasms
mycobacterium bovis
administration/intravesical
neoplasm recurrence/local
antineoplastic agents
description The management of non-muscle-invasive urothelial carcinoma of the bladder (UCB) is a challenge for physicians and patients alike. This is largely due to the heterogeneous natural history of this disease, in which tumors range from indolent to rapidly progressive and eventually fatal. Moreover, the high rate of recurrence and progression cause significant morbidity, expense, and detriment to quality of life. The advent of effective and safe intravesical therapies has improved the management of non-muscle-invasive UCB. Nevertheless, despite over 30 years of research and clinical experience, the mechanism, risks, benefits, and optimal regimens and treatment algorithms remain unclear. Although immunotherapy with bacillus Calmette-Guerin (BCG) has been the mainstay of intravesical treatment and represents a significant advance in the interaction of immunology and oncology, its clinical effectiveness is accompanied by a wide range of adverse events. Here, we review the literature on intravesical immunotherapy and chemotherapy with the aim of evaluating the clinical utility of the different treatments and providing recommendations. Many studies over the years have compared efficacy and toxicities of different agents and regimens, and certain conclusions are now well supported by high-level evidence. Future perspectives and promising advances in drug development are discussed and areas of improvement are identified in order to promote better cancer control and decrease the rate and severity of side-effects.
publishDate 2009
dc.date.none.fl_str_mv 2009-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382009000600002
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382009000600002
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1677-55382009000600002
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.35 n.6 2009
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318071312023552